0000000000026462

AUTHOR

Vicente Guillem

showing 15 related works from this author

Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case–control EpiGEICAM study

2014

BACKGROUND: Although there are solid findings regarding the detrimental effect of alcohol consumption, the existing evidence on the effect of other dietary factors on breast cancer (BC) risk is inconclusive. This study aimed to evaluate the association between dietary patterns and risk of BC in Spanish women, stratifying by menopausal status and tumour subtype, and to compare the results with those of Alternate Healthy Index (AHEI) and Alternate Mediterranean Diet Score (aMED). METHODS: We recruited 1017 incident BC cases and 1017 matched healthy controls of similar age (±5 years) without a history of BC. The association between 'a priori' and 'a posteriori' developed dietary patterns and B…

RiskCancer Researchmedicine.medical_specialtyMediterranean dietEpidemiologyprincipal component analysisdietary patternsTriple Negative Breast NeoplasmsaMEDLower riskDiet MediterraneanMediterranean patternBreast cancermedicinebreast neoplasmsOily fishHumansbusiness.industryAHEIIncidence (epidemiology)IncidenceCase-control studyDietary patternmedicine.diseaseSurgeryOncologyQuartileSpainCase-Control StudiesFemalebusinessDemography
researchProduct

The Quality Oncology Practice Initiative program: Experience in Spain.

2017

214 Background: Patient care quality is a discipline that is being considered highly important in today’s healthcare. Quality Oncology Practice Initiative (QOPI) is a referral worldwide in terms of quality for oncology practices. The ECO Foundation is a platform of experts representing the major Spanish hospitals involved in the treatment of cancer patients. ECO reached an agreement with QOPI in order to involve Spanish hospitals in the participation of the QOPI program. Methods: Two rounds of data collection were carried out (Fall 2015 and Spring 2016). Practices had to registered on-line and submit data into the platform provided by QOPI. ECO Foundation offers all centres the support of …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyData collectionReferralbusiness.industrymedia_common.quotation_subjectPatient care03 medical and health sciences030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineFamily medicineHealth caremedicineQuality (business)businessmedia_commonJournal of Clinical Oncology
researchProduct

Evaluation of Spanish hospitals participating in the Quality Oncology Practice Initiative program.

2020

222 Background: Measuring and tracking quality of care is highly relevant in today’s healthcare. The Quality Oncology Practice Initiative (QOPI) program is a referral for evaluating oncology practices worldwide. The ECO Foundation (Excellence and Quality in Oncology), a collaboration of oncology experts from the major Spanish hospitals involved in cancer treatment, reached an agreement with ASCO (American Society of Clinical Oncology) to include Spanish hospitals in its QOPI program. Methods: We analyzed the results of the QOPI core module measures from 19 Spanish hospitals submitting their data in nine rounds (from Fall 2015 to Fall 2019). Results: Of the 19 hospitals, 15 participated mor…

OncologyCancer Researchmedicine.medical_specialtyReferralbusiness.industrymedia_common.quotation_subjectOncologyInternal medicineHealth caremedicineQuality (business)Tracking (education)Quality of carebusinessmedia_commonJournal of Clinical Oncology
researchProduct

QIM19-135: The Quality Oncology Practice Initiative Program: Experience in Spain

2019

Background: Patient quality care is a discipline that has acquired enormous relevance in today’s healthcare. The Quality Oncology Practice Initiative (QOPI) is a referral worldwide in terms of quality for oncology practices. The ECO Foundation is a foundation of experts representing the major Spanish hospitals involved in the treatment of cancer patients. ECO reached an agreement with ASCO to involve Spanish hospitals in the QOPI program. Methods: 6 rounds of data collection have taken place (Fall 2015 to Round 1 2018). Practices had to register online and submit data into the QOPI platform, and the ECO Foundation offered all centers the necessary support. 17 Spanish hospitals have particip…

OncologyNursingbusiness.industrymedia_common.quotation_subjectMedicineQuality (business)businessmedia_commonJournal of the National Comprehensive Cancer Network
researchProduct

Lower Breast Cancer Risk among Women Following Lifestyle Recommendations: A Case-Control Study in Spain.

2015

Oncologymedicine.medical_specialtyBreast cancerEpidemiologybusiness.industryInternal medicineFamily medicinemedicineCase-control studyGeneral Medicinebusinessmedicine.diseaseInternational Journal of Epidemiology
researchProduct

Identification of quality care indicators in prostate cancer.

2017

213 Background: Despite the attempts made to improve prostate cancer management with the development and implementation of clinical practice guidelines, the inefficiencies and differences that usually occur in ordinary clinical care of patients with prostate cancer significantly contribute to increase the variations in the patterns of care and patients outcomes, and costs to the health system. The goal of this project was to establish parameters for improving the care of patients with prostate cancer through the development and validation of quality indicators for the management of this disease. Methods: The ECO Foundation is a platform of experts representing the major Spanish hospitals i…

Cancer Researchmedicine.medical_specialtybusiness.industrymedia_common.quotation_subjectQuality careCancerDiseasemedicine.diseaseIdentification (information)Prostate cancerOncologyMultidisciplinary approachFamily medicinemedicinePhysical therapyQuality (business)businessMedical literaturemedia_commonJournal of Clinical Oncology
researchProduct

Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies

2007

Therapy-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) is a malignancy occurring after exposure to chemotherapy and/or radiotherapy. Polymorphisms involved in chemotherapy/radiotherapy response genes could be related to an increased risk of developing this neoplasia. We have studied 11 polymorphisms in genes of drug detoxification pathways (NQO1, glutathione S-transferase pi) and DNA repair xeroderma pigmentosum, complementation group (3) (XPC(3), X-ray repair cross complementing protein (1)), Nijmegen breakage syndrome (1), excision repair cross-complementing rodent repair deficiency, complementation group (5) and X-ray repair cross complementing protein (3) and in the methy…

OncologyCancer Researchmedicine.medical_specialtyXeroderma pigmentosumAntineoplastic AgentsBreast NeoplasmsSingle-nucleotide polymorphismPolymorphism Single NucleotideBreast cancerRisk Factorshemic and lymphatic diseasesInternal medicinemedicineHumansMethylenetetrahydrofolate Reductase (NADPH2)Leukemiabiologybusiness.industryHaplotypeMyeloid leukemiaNeoplasms Second PrimaryHematologyMiddle Agedmedicine.diseaseHaplotypesOncologyCase-Control StudiesHematologic NeoplasmsMethylenetetrahydrofolate reductaseImmunologybiology.proteinbusinessNijmegen breakage syndromeNucleotide excision repairLeukemia
researchProduct

Implementation of the quality training program in Spain.

2019

e18296 Background: The ECO Foundation is a collaboration of experts representing the major Spanish hospitals in the pursuit of excellence in cancer treatment. Since 2015, ECO has been collaborating with ASCO (American Society of Clinical Oncology) in quality initiatives in cancer care, like the QOPI (Quality Oncology Practice Initiative) program and the QOPI Certification Program (QCP). The Quality Training Program (QTP) is a 6-month program with 3 in-person learning sessions that prepares oncology teams to design implement and lead successful quality improvement activities in their practices. In 2018, ECO reached a new agreement with ASCO to implement this program in Spain. Methods: The Q…

Medical educationCancer ResearchOncologyExcellencebusiness.industrymedia_common.quotation_subjectMedicineFoundation (evidence)Quality (business)Training programbusinessmedia_commonCancer treatmentJournal of Clinical Oncology
researchProduct

Development of an MCDA framework for evaluation and positioning of oncological treatments in clinical practice.

2019

95 Background: Ensuring that effective innovations are accessible in a timely and affordable manner to all cancer patients is a challenge that stakeholders face today. Several oncology frameworks (ASCO, ESMO, ICER, NCCN) have been developed to define and quantify the value of oncological therapies to support clinicians and patients at the time of selection and as a basis for decision-making. However, current frameworks only define treatment value in terms of clinical benefit, creating a need for one that allows holistic evaluation of treatments and supports decision-making in clinical practice. The ECO Foundation led this study to develop a reflective multi-criteria decision analysis (MCDA…

Clinical PracticeCancer Researchmedicine.medical_specialtyOncologybusiness.industryMedicineCancerMedical physicsMultiple-criteria decision analysisbusinessmedicine.diseaseJournal of Clinical Oncology
researchProduct

Delphi Consensus on the Follow-up of Cancer Patients with Breakthrough Pain Under Opioid Treatment

2019

e23135 Background: Breakthrough cancer pain (BTcP) is one of the most common symptoms related with the disease and its treatment. Its management differs from that of chronic pain but there is not a wide consensus about fundamental aspects of BTcP definition, diagnosis, follow-up, and management. The objective of this study promoted by ECO Foundation, is to reach a consensus on the follow-up of patients with BTcP under opioid treatment. Methods: This work was conducted using a modified Delphi method organized in two rounds and involving a panel of 84 medical oncologists. A questionnaire of 66 items was developed. The items proposed to reach a consensus included the following topics: 1) When…

Cancer Researchmedicine.medical_specialtybusiness.industryBreakthrough PainChronic painCancerDiseasemedicine.diseaseOncologyOpioidPain controlInternal medicineMedicinebusinessIntensive care medicineCancer paincomputerDelphimedicine.drugcomputer.programming_languageSN Comprehensive Clinical Medicine
researchProduct

Assessment and treatment of breakthrough cancer pain in Spain: A self-audit study.

2018

e18785Background: Breakthrough cancer pain (BTcP) is a common condition, but its management may be often suboptimal. We aim to determine if physician’s perception of the management and characterist...

Cancer ResearchAudit studymedicine.medical_specialtygenetic structuresOncologybusiness.industryPerceptionmedia_common.quotation_subjectPhysical therapyMedicinebusinessCancer painmedia_commonJournal of Clinical Oncology
researchProduct

Breast cancer risk among women following lifestyle recommendations: A case-control study in Spain.

2014

1602 Background: In 2007, the World Cancer Research Fund (WCRF) and the American Institute of Cancer Research (AICR) issued 8 general and 2 special recommendations for cancer prevention based on av...

GerontologyCancer ResearchBreast cancerCancer preventionOncologybusiness.industrymedicineCase-control studymedicine.diseasebusinessJournal of Clinical Oncology
researchProduct

Proliferation-, estrogen-, and T-cell-related metagenes to predict outcome after adjuvant/neoadjuvant chemotherapy for operable breast cancer in the …

2013

1014 Background: Predicting recurrence in operable breast cancer (BC) despite optimal chemotherapy would be relevant to new drug development and tailored treatments. Methods: A large series (n=3,154) of public Affymetrix gene-expression profiles (GEP) was used to define prognostic/predictive metagenes in different BC subtypes. In ER+/HER2- a proliferation and an ER-related metagene were combined to predict low, intermediate and high risk of recurrence. In TN and in HER2+ a T cell metagene was used to predict low, intermediate and high risk (higher expression associated with lower risk). The metagenes were validated in patients enrolled in the phase III ECTO trial (Gianni L. JCO 2009) and t…

OncologyCancer Researchmedicine.medical_specialtyChemotherapymedicine.drug_classbusiness.industrymedicine.medical_treatmentT cellLarge seriesmedicine.diseaseBreast cancermedicine.anatomical_structureOncologyDrug developmentEstrogenInternal medicinemedicinebusinessAdjuvantJournal of Clinical Oncology
researchProduct

Freedom from progression (FFP) by adding paclitaxel (T) to doxorubicin (A) followed by CMF as adjuvant or primary systemic therapy: 10-yr results of …

2013

537 Background: At the time the ECTO was designed in 1996, taxanes were only indicated for patients with metastatic breast cancer. However, paclitaxel and docetaxel were still to be tested in the adjuvant setting. In addition there was relatively scarce information on the comparative efficacy of neoadjuvant and adjuvant regimens. The ECTO trial was designed to evaluate the addition of paclitaxel to an anthracycline-based adjuvant regimen and to compare this combination with the same regimen given as primary systemic (neoadjuvant) therapy. Methods: A total of 1,355 women with operable breast cancer were randomized to one of three treatments: 1) surgery followed by adjuvant single agent doxo…

OncologyCancer Researchmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentmedicine.diseaseSystemic therapyMetastatic breast cancerchemistry.chemical_compoundBreast cancerOncologyDocetaxelPaclitaxelchemistryInternal medicineFreedom from progressionmedicineDoxorubicinbusinessAdjuvantmedicine.drugJournal of Clinical Oncology
researchProduct

Non-clinical needs of cancer patients in Spain under different perspectives: A comparative study.

2019

e18266 Background: Patients with cancer and their caregivers express unmet needs beyond the clinical approach to cancer. The ECO Foundation (Quality and Excellence in Oncology) and the Spanish Association Against Cancer (AECC) have promoted a qualitative research study with the objective to compare the perceptions of newly diagnosed and 2-3 years after diagnosis cancer patients, caregivers, oncologists, nurses and social workers in relation to a set of non-clinical needs expressed by cancer patients and caregivers, and to obtain concrete and feasible proposals for improvement aimed at satisfying these needs. Methods: A multidisciplinary group of experts developed a questionnaire containing…

Cancer Researchmedicine.medical_specialtybusiness.industrymedia_common.quotation_subjectFoundation (evidence)Cancermedicine.diseaseUnmet needsOncologyNon clinicalExcellenceFamily medicineMedicineQuality (business)businessmedia_commonJournal of Clinical Oncology
researchProduct